What Can We Learn from Intraoperative Parathyroid Hormone Levels that Do Not Drop Appropriately?

Annals of Surgical Oncology

Volumn 22, Issue 6, 2015, Pages 1781-1788

  Wachtel, Heather ^a   Cerullo, Isadora ^a   Bartlett, Edmund K ^a   Kelz, Rachel R ^a   Karakousis, Giorgos C ^a   Fraker, Douglas L ^a  

^a HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PARATHYROID HORMONE;

ADULT; AGED; BLOOD; FEMALE; FOLLOW UP; HUMAN; HYPERPARATHYROIDISM, PRIMARY; MALE; MIDDLE AGED; PARATHYROIDECTOMY; PATIENT MONITORING; PROGNOSIS; RETROSPECTIVE STUDY; UTILIZATION;

ADULT; AGED; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYPERPARATHYROIDISM, PRIMARY; MALE; MIDDLE AGED; MONITORING, INTRAOPERATIVE; PARATHYROID HORMONE; PARATHYROIDECTOMY; PROGNOSIS; RETROSPECTIVE STUDIES;

EID: 84939937668     PISSN: 10689265     EISSN: 15344681     Source Type: Journal    
DOI: 10.1245/s10434-014-4201-9     Document Type: Article

References (34)

1. Yu N, Donnan PT, Murphy MJ, Leese GP. Epidemiology of primary hyperparathyroidism in Tayside, Scotland, UK. Clin Endocrinol. 2009;71:485–93.
2. Wermers RA, Khosla S, Atkinson EJ, et al. Incidence of primary hyperparathyroidism in Rochester, Minnesota, 1993–2001: an update on the changing epidemiology of the disease. J Bone Miner Res. 2006;21:171–7.
3. Yeh MW, Ituarte PH, Zhou HC, et al. Incidence and prevalence of primary hyperparathyroidism in a racially mixed population. J Clin Endocrinol Metab. 2013;98:1122–9.
4. Lew JI, Solorzano CC. Surgical management of primary hyperparathyroidism: state of the art. Surg Clin North Am. 2009;89:1205–25.
5. Simental A, Ferris RL. Reoperative parathyroidectomy. Otolaryngol Clin North Am. 2008;41:1269–74, xii.
6. van Heerden JA, Grant CS. Surgical treatment of primary hyperparathyroidism: an institutional perspective. World J Surg. 1991;15:688–92. doi:10.1007/BF01665301
7. Hasse C, Sitter H, Brune M, Wollenteit I, Nies C, Rothmund M. Quality of life and patient satisfaction after reoperation for primary hyperparathyroidism: analysis of long-term results. World J Surg. 2002;26:1029–36. doi:10.1007/s00268-002-6664-2
8. Karakas E, Muller HH, Schlosshauer T, Rothmund M, Bartsch DK. Reoperations for primary hyperparathyroidism—improvement of outcome over two decades. Langenbeck Arch Surg. 2013;398:99–106.
9. Carty SE, Norton JA. Management of patients with persistent or recurrent primary hyperparathyroidism. World J Surg. 1991;15:716–23. doi:10.1007/BF01665305
10. Brennan MF, Norton JA. Reoperation for persistent and recurrent hyperparathyroidism. Ann Surg. 1985;201:40–4.
11. Jaskowiak N, Norton JA, Alexander HR, et al. A prospective trial evaluating a standard approach to reoperation for missed parathyroid adenoma. Ann Surg. 1996;224:308–20.
12. Cheung PS, Borgstrom A, Thompson NW. Strategy in reoperative surgery for hyperparathyroidism. Arch Surg. 1989;124:676–80.
13. Granberg PO, Johansson G, Lindvall N, et al. Reoperation for primary hyperparathyroidism. Am J Surg. 1982;143:296–300.
14. Doherty GM, Weber B, Norton JA. Cost of unsuccessful surgery for primary hyperparathyroidism. Surgery. 1994;116:954–7.
15. Caron NR, Sturgeon C, Clark OH. Persistent and recurrent hyperparathyroidism. Curr Treat Options Oncol. 2004;5:335–45.
16. Carsello CB, Yen TW, Wang TS. Persistent elevation in serum parathyroid hormone levels in normocalcemic patients after parathyroidectomy: does it matter? Surgery. 2012;152:575–81.
17. Wang TS, Ostrower ST, Heller KS. Persistently elevated parathyroid hormone levels after parathyroid surgery. Surgery. 2005;138:1130–5.
18. Yen TW, Wilson SD, Krzywda EA, Sugg SL. The role of parathyroid hormone measurements after surgery for primary hyperparathyroidism. Surgery. 2006;140:665–72.
19. Karakousis GC, Han D, Kelz RR, et al. Interpretation of intra-operative PTH changes in patients with multi-glandular primary hyperparathyroidism (pHPT). Surgery. 2007;142:845–50.
20. McCoy KL, Chen NH, Armstrong MJ, et al. The small abnormal parathyroid gland is increasingly common and heralds operative complexity. World J Surg. 2014;38:1274–81. doi:10.1007/s00268-014-2450-1
21. Moretz WH 3rd, Watts TL, Virgin FW Jr, Chin E, Gourin CG, Terris DJ. Correlation of intraoperative parathyroid hormone levels with parathyroid gland size. Laryngoscope. 2007;117:1957–60.
22. Sebag F, Hubbard JG, Maweja S, Misso C, Tardivet L, Henry JF. Negative preoperative localization studies are highly predictive of multiglandular disease in sporadic primary hyperparathyroidism. Surgery. 2003;134:1038–41.
23. Civelek AC, Ozalp E, Donovan P, Udelsman R. Prospective evaluation of delayed technetium-99 m sestamibi SPECT scintigraphy for preoperative localization of primary hyperparathyroidism. Surgery. 2002;131:149–57.
24. Mihai R, Gleeson F, Buley ID, Roskell DE, Sadler GP. Negative imaging studies for primary hyperparathyroidism are unavoidable: correlation of sestamibi and high-resolution ultrasound scanning with histological analysis in 150 patients. World J Surg. 2006;30:697–704. doi:10.1007/s00268-005-0338-9
25. Erbil Y, Barbaros U, Tukenmez M, et al. Impact of adenoma weight and ectopic location of parathyroid adenoma on localization study results. World J Surg. 2008;32:566–71. doi:10.1007/s00268-007-9389-4
26. Heller KS, Blumberg SN. Relation of final intraoperative parathyroid hormone level and outcome following parathyroidectomy. Arch Otolaryngol Head Neck Surg. 2009;135:1103–7.
27. Wharry LI, Yip L, Armstrong MJ, et al. The final intraoperative parathyroid hormone level: how low should it go? World J Surg. 2014;38:558–63. doi:10.1007/s00268-013-2329-6
28. Chiu B, Sturgeon C, Angelos P. What is the link between nonlocalizing sestamibi scans, multigland disease, and persistent hypercalcemia? A study of 401 consecutive patients undergoing parathyroidectomy. Surgery. 2006;140:418–22.
29. Sosa JA, Powe NR, Levine MA, Udelsman R, Zeiger MA. Profile of a clinical practice: thresholds for surgery and surgical outcomes for patients with primary hyperparathyroidism: a national survey of endocrine surgeons. J Clin Endocrinol Metab. 1998;83:2658–65.
30. Rudberg C, Akerstrom G, Palmer M, et al. Late results of operation for primary hyperparathyroidism in 441 patients. Surgery. 1986;99:643–51.
31. Doherty GM, Doppman JL, Miller DL, et al. Results of a multidisciplinary strategy for management of mediastinal parathyroid adenoma as a cause of persistent primary hyperparathyroidism. Ann Surg. 1992;215:101–6.
32. Kraimps JL, Denizot A, Carnaille B, et al. Primary hyperparathyroidism in multiple endocrine neoplasia type IIa: retrospective French multicentric study. Groupe d’Etude des Tumeurs a Calcitonine (GETC, French Calcitonin Tumors Study Group), French Association of Endocrine Surgeons. World J Surg. 1996;20:808–12. doi:10.4103/2230-8210.113774
33. Gertner ME, Kebebew E. Multiple endocrine neoplasia type 2. Curr Treat Options Oncol. 2004;5:315–25.
34. Barry MK, van Heerden JA, Grant CS, Thompson GB, Khosla S. Is familial hyperparathyroidism a unique disease? Surgery. 1997;122:1028–33.